Current regulatory requirements for stability studies of biological medicinal products: a review

INTRODUCTION. The stability assessment of biological medicinal products (BMPs) requires special approaches and regulatory requirements. Therefore, BMPs require relevant national guidelines, which are an important prerequisite for the assurance of the safe and effective use of BMPs.AIM. This study ai...

Full description

Saved in:
Bibliographic Details
Main Authors: A. A. Soldatov, A. K. Yakovlev, Zh. I. Avdeeva, D. V. Gorenkov, A. S. Korovkin, V. V. Kosenko
Format: Article
Language:Russian
Published: Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products» 2024-10-01
Series:Биопрепараты: Профилактика, диагностика, лечение
Subjects:
Online Access:https://www.biopreparations.ru/jour/article/view/613
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849242944967540736
author A. A. Soldatov
A. K. Yakovlev
Zh. I. Avdeeva
D. V. Gorenkov
A. S. Korovkin
V. V. Kosenko
author_facet A. A. Soldatov
A. K. Yakovlev
Zh. I. Avdeeva
D. V. Gorenkov
A. S. Korovkin
V. V. Kosenko
author_sort A. A. Soldatov
collection DOAJ
description INTRODUCTION. The stability assessment of biological medicinal products (BMPs) requires special approaches and regulatory requirements. Therefore, BMPs require relevant national guidelines, which are an important prerequisite for the assurance of the safe and effective use of BMPs.AIM. This study aimed to analyse national and international requirements for the stability assessment of BMPs in order to use the results to inform future development of a unified regulatory approach to estimating and confirming shelf-life periods for BMPs.DISCUSSION. Most biotechnological medicinal products (BTMPs) are proteins and are highly sensitive to environmental factors by nature. Therefore, the shelf life of a BTMP is established on the basis of real-time stability studies. Stability testing under accelerated and stress conditions is conducted to support shelf-life claims and to characterise the mechanism of protein structure degradation. The results of accelerated and stress studies can be used to select the most sensitive stability-indicating parameters and testing methods. National and international regulatory authorities have developed specialised guidelines for stability studies of BMPs of various origins, and the stability assessment approaches in the regulatory system of the Eurasian Economic Union (EAEU) are harmonised with international standards. Special considerations associated with the stability of vaccines imply that stability studies of vaccines should not only establish shelf life but also investigate stability after reconstitution and after short-term temperature excursions from the recommended cold-chain conditions.CONCLUSIONS. Special stability testing considerations for various groups of BMPs (including BTMPs and immunobiologicals) indicate the need to develop and improve the system of requirements for BMP stability assessment. This will facilitate the optimisation of the life cycle of BMPs in the Russian Federation and the other EAEU member states.
format Article
id doaj-art-a7794b50a9b84a0e9ce7418b155c8c81
institution Kabale University
issn 2221-996X
2619-1156
language Russian
publishDate 2024-10-01
publisher Ministry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
record_format Article
series Биопрепараты: Профилактика, диагностика, лечение
spelling doaj-art-a7794b50a9b84a0e9ce7418b155c8c812025-08-20T03:59:39ZrusMinistry of Health of the Russian Federation. Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»Биопрепараты: Профилактика, диагностика, лечение2221-996X2619-11562024-10-0124333534710.30895/2221-996X-2024-24-3-335-347388Current regulatory requirements for stability studies of biological medicinal products: a reviewA. A. Soldatov0A. K. Yakovlev1Zh. I. Avdeeva2D. V. Gorenkov3A. S. Korovkin4V. V. Kosenko5Scientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsScientific Centre for Expert Evaluation of Medicinal ProductsINTRODUCTION. The stability assessment of biological medicinal products (BMPs) requires special approaches and regulatory requirements. Therefore, BMPs require relevant national guidelines, which are an important prerequisite for the assurance of the safe and effective use of BMPs.AIM. This study aimed to analyse national and international requirements for the stability assessment of BMPs in order to use the results to inform future development of a unified regulatory approach to estimating and confirming shelf-life periods for BMPs.DISCUSSION. Most biotechnological medicinal products (BTMPs) are proteins and are highly sensitive to environmental factors by nature. Therefore, the shelf life of a BTMP is established on the basis of real-time stability studies. Stability testing under accelerated and stress conditions is conducted to support shelf-life claims and to characterise the mechanism of protein structure degradation. The results of accelerated and stress studies can be used to select the most sensitive stability-indicating parameters and testing methods. National and international regulatory authorities have developed specialised guidelines for stability studies of BMPs of various origins, and the stability assessment approaches in the regulatory system of the Eurasian Economic Union (EAEU) are harmonised with international standards. Special considerations associated with the stability of vaccines imply that stability studies of vaccines should not only establish shelf life but also investigate stability after reconstitution and after short-term temperature excursions from the recommended cold-chain conditions.CONCLUSIONS. Special stability testing considerations for various groups of BMPs (including BTMPs and immunobiologicals) indicate the need to develop and improve the system of requirements for BMP stability assessment. This will facilitate the optimisation of the life cycle of BMPs in the Russian Federation and the other EAEU member states.https://www.biopreparations.ru/jour/article/view/613biological medicinal productsbiotechnological medicinal productsstability studiesvaccine stabilityaccelerated stability studiesstability studies under stress conditionslong-term stability studiesshelf lifethermal stabilityphotostability
spellingShingle A. A. Soldatov
A. K. Yakovlev
Zh. I. Avdeeva
D. V. Gorenkov
A. S. Korovkin
V. V. Kosenko
Current regulatory requirements for stability studies of biological medicinal products: a review
Биопрепараты: Профилактика, диагностика, лечение
biological medicinal products
biotechnological medicinal products
stability studies
vaccine stability
accelerated stability studies
stability studies under stress conditions
long-term stability studies
shelf life
thermal stability
photostability
title Current regulatory requirements for stability studies of biological medicinal products: a review
title_full Current regulatory requirements for stability studies of biological medicinal products: a review
title_fullStr Current regulatory requirements for stability studies of biological medicinal products: a review
title_full_unstemmed Current regulatory requirements for stability studies of biological medicinal products: a review
title_short Current regulatory requirements for stability studies of biological medicinal products: a review
title_sort current regulatory requirements for stability studies of biological medicinal products a review
topic biological medicinal products
biotechnological medicinal products
stability studies
vaccine stability
accelerated stability studies
stability studies under stress conditions
long-term stability studies
shelf life
thermal stability
photostability
url https://www.biopreparations.ru/jour/article/view/613
work_keys_str_mv AT aasoldatov currentregulatoryrequirementsforstabilitystudiesofbiologicalmedicinalproductsareview
AT akyakovlev currentregulatoryrequirementsforstabilitystudiesofbiologicalmedicinalproductsareview
AT zhiavdeeva currentregulatoryrequirementsforstabilitystudiesofbiologicalmedicinalproductsareview
AT dvgorenkov currentregulatoryrequirementsforstabilitystudiesofbiologicalmedicinalproductsareview
AT askorovkin currentregulatoryrequirementsforstabilitystudiesofbiologicalmedicinalproductsareview
AT vvkosenko currentregulatoryrequirementsforstabilitystudiesofbiologicalmedicinalproductsareview